Skip to main content

Table 3 Differences in EMB/INH/RIF resistance by age, race, and HIV status, by county DOT program type1

From: Does directly observed therapy (DOT) reduce drug resistant tuberculosis?

 

Selective DOT county

Universal DOT county

    
 

(n = 1207)

(n = 514)

   

Interaction

Stratifying factor

No. Resistant

(%)

No. Resistant

(%)

OR

(95% CI)

p-value

p-value2

Age (yrs)

       

0.06

   <30

28

(9)

8

(7)

1.3

(0.5, 2.9)

0.58

 

   30 - 59

59

(8)

15

(5)

1.7

(0.9, 3.1)

0.08

 

   60+

8

(5)

2

(2)

2.1

(0.4, 10.2)

0.36

 

Race

       

0.11

   Black

41

(8)

6

(4)

2.1

(0.9, 5.1)

0.09

 

   Hispanic

20

(6)

10

(8)

0.7

(0.3, 1.5)

0.34

 

   White

8

(4)

3

(2)

1.4

(0.3, 5.6)

0.65

 

   Asian/other

26

(18)

6

(8)

2.8

(1.1, 7.1)

0.03

 

HIV status

       

0.52

   Negative

74

(7)

20

(4)

1.6

(1.0, 2.7)

0.07

 

   Positive

21

(11)

5

(8)

1.2

(0.4, 3.6)

0.68

 
  1. 1Separate analyses were done for each level of each stratifying factor; e.g., among patients aged <30, 28 (9%) patients from selective DOT and 8 (7%) from universal DOT were resistant, with an OR of 1.3 associating increased resistance with selective DOT. Analyses were adjusted for age, race, and/or HIV status, as appropriate, depending on the stratification factor.
  2. 2Interaction between DOT program and the stratifying factor.
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us